CIGNA Co. (NYSE:CI) – Equities researchers at Oppenheimer issued their Q1 2019 earnings per share (EPS) estimates for shares of CIGNA in a report issued on Tuesday. Oppenheimer analyst M. Wiederhorn anticipates that the health services provider will post earnings of $3.27 per share for the quarter. Oppenheimer also issued estimates for CIGNA’s Q2 2019 earnings at $3.30 EPS, Q3 2019 earnings at $3.21 EPS, Q4 2019 earnings at $2.69 EPS and FY2019 earnings at $12.47 EPS.

CIGNA (NYSE:CI) last released its quarterly earnings data on Thursday, November 2nd. The health services provider reported $2.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.36 by $0.47. The firm had revenue of $10.38 billion for the quarter, compared to analyst estimates of $10.17 billion. CIGNA had a net margin of 5.74% and a return on equity of 18.85%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.94 earnings per share.

CI has been the topic of a number of other reports. Zacks Investment Research raised shares of CIGNA from a “hold” rating to a “buy” rating and set a $214.00 price target on the stock in a report on Monday, October 9th. Jefferies Group increased their price target on shares of CIGNA from $201.00 to $221.00 and gave the stock a “buy” rating in a report on Friday, October 13th. BMO Capital Markets assumed coverage on shares of CIGNA in a report on Monday, October 16th. They set a “market perform” rating and a $210.00 price target on the stock. Credit Suisse Group assumed coverage on shares of CIGNA in a report on Thursday, November 2nd. They set an “outperform” rating and a $219.00 price target on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $220.00 price target (up from $185.00) on shares of CIGNA in a report on Friday, November 3rd. Three equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $205.18.

CIGNA (NYSE:CI) traded up $5.61 during trading hours on Wednesday, hitting $220.36. 1,410,904 shares of the stock were exchanged, compared to its average volume of 1,210,000. The firm has a market capitalization of $54,330.00, a price-to-earnings ratio of 24.14, a P/E/G ratio of 1.42 and a beta of 0.51. CIGNA has a 1 year low of $133.52 and a 1 year high of $221.13. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.39 and a quick ratio of 0.39.

In other CIGNA news, insider Michael W. Triplett sold 10,417 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $197.77, for a total transaction of $2,060,170.09. Following the transaction, the insider now directly owns 32,347 shares of the company’s stock, valued at $6,397,266.19. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Mary T. Hoeltzel sold 575 shares of the stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $197.03, for a total transaction of $113,292.25. Following the transaction, the chief accounting officer now directly owns 2,499 shares in the company, valued at $492,377.97. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,556 shares of company stock worth $14,160,975. Insiders own 1.30% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. lifted its stake in shares of CIGNA by 3.4% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 904,143 shares of the health services provider’s stock worth $183,623,000 after buying an additional 29,553 shares in the last quarter. Creative Planning lifted its stake in shares of CIGNA by 23.3% in the fourth quarter. Creative Planning now owns 18,250 shares of the health services provider’s stock worth $3,706,000 after buying an additional 3,447 shares in the last quarter. National Pension Service lifted its stake in shares of CIGNA by 1.6% in the fourth quarter. National Pension Service now owns 223,263 shares of the health services provider’s stock worth $45,342,000 after buying an additional 3,577 shares in the last quarter. E&G Advisors LP lifted its stake in shares of CIGNA by 109.1% in the fourth quarter. E&G Advisors LP now owns 2,300 shares of the health services provider’s stock worth $467,000 after buying an additional 1,200 shares in the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of CIGNA by 30.0% in the fourth quarter. Bank of Montreal Can now owns 1,232,172 shares of the health services provider’s stock worth $250,243,000 after buying an additional 284,384 shares in the last quarter. 87.75% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/17/analysts-offer-predictions-for-cigna-co-s-q1-2019-earnings-ci.html.

About CIGNA

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Earnings History and Estimates for CIGNA (NYSE:CI)

Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.